The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000766314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
29/05/2026
Date registered
Help: Date registered
26/06/2026
Date last updated
Help: Date last updated
26/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Implementation of BRIDGE (Building Rural medication safety through Interdisciplinary, Data-driven, clinical Governance focused on Equity): A Feasibility Study
Scientific title
Evaluating the feasibility of implementing BRIDGE (Building Rural medication safety through Interdisciplinary, Data-driven, clinical Governance focused on Equity) in Australian rural practices to facilitate home medication reviews in priority patient groups.
Additional trial identifiers [1] 317264 0
NHMRC App 2043753
Universal Trial Number (UTN)
Trial acronym
BRIDGE (Building Rural medication safety through Interdisciplinary, Data-driven, clinical Governance focused on Equity)
Related trial records

Health condition
Health condition(s) studied:
Polypharmacy 341886 0
Medication-related harm 341887 0
Chronic disease management 341889 0
Multimorbidity 341890 0
Condition category
Condition code
Public Health 337949 337949 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
1. Intervention:
This feasibility study evaluates a technology-enabled intervention designed to support medication safety within five rural general practice. The intervention consists of deploying a health information technology framework to evaluate how rural general practice systems can identify and track care pathways for patients meeting predefined medication-risk metrics. It also facilitates GP–pharmacist communication and coordinated referrals through a secure tracking system, supporting referral completion, pharmacist feedback to GPs, and improved patient understanding and management of their medicines.
The tools include:
1.1. Electronic case-finding: The BRIDGE research team collaborated with PenCS to co-develop and integrate a cloud-based electronic case-finding dashboard (PenCS-BRIDGE) within general practice systems. The dashboard systematically identifies priority patients using prescribing-related medication safety indicators and Australian HMR referral criteria.
1.2. Coordinated care workflow: In collaboration with Simple HealthCare Solutions, the study will utilise a secure, dedicated digital tracking platform (HMR Tracker by Simple HealthCare Solutions) to facilitate GP-pharmacist communication, streamline the referral pathway, monitor referral completion, and securely transmit pharmacist feedback reports to the general practitioners (GPs).
Indicators used in the development of case-finding tool:
1. Co-prescriptions of medicines with renal risk (e.g., (Angiotensin-Converting Enzyme inhibitors/Angiotensin Receptor Blockers, diuretics, Non-Steroidal Anti-inflammatory Drugs, lithium, quinolones, sulfonamide, etc).
2. Long-term antipsychotics and no fasting serum lipids in the previous 6 months (olanzapine) and in the previous 12 months (all others).
3. Asthma/ Chronic Obstructive Pulmonary Disease and no record of influenza vaccine in the previous year.
4. Co-prescription of falls/fractures risk medications (e.g., opioid, benzodiazepine, antidepressants, antihypertensives)
5. Co-prescription of opioid and benzodiazepine for 3 months or more
6. 65 years (or older) with a history of falls/fracture with co-prescription of falls/fracture risk medications (e.g., opioid, benzodiazepine, antidepressants, antihypertensives etc.)
7. Co-prescription of QT prolonging drugs (e.g., amiodarone, haloperidol, fluconazole, citalopram etc.)
8. Myocardial infarction or heart failure with a prescription of Non-Steroidal Anti-inflammatory Drugs
9. Long-term PPI therapy (more than 8 weeks) without a history of gastrointestinal ulcer or use of high-risk medications (e.g., antithrombotic)


2. Who will deliver the intervention?
The intervention is a software-and-workflow feasibility utilised by existing clinic staff within their routine operational roles:
2.1 Practice Staff (Nurses and GPs): Access the case-finding dashboard and tracking platforms to evaluate how these tools fit into existing daily practice activities.
2.2 Credentialed Pharmacists: Practice nominated credentialed pharmacists will access the HMR tracker to interact with GP generated medication review referrals and will provide feedback documentation to the GPs. Practice nurses will support patient identification, workflow coordination, and implementation processes within the practice. Participating GPs will facilitate HMR workflows, by engaging with eligible patients to start the HMR review process, submit the referral letter and discuss the HMR report with the patient, so that medication management strategies are agreed.
2.3 Technology Partners (PenCS and Simple HealthCare Solutions): Deliver the software installation, technical optimisation, and standardised user training to the participating clinic staff

3. Mode of Delivery:
The intervention is delivered entirely at the organisational level via remote digital health delivery methods:
3.1 Technical Deployment: Remote software configuration and deployment into the existing IT infrastructure of the five participating clinics.
3.2 Provider Training: Delivered virtually via Microsoft Teams through a mix of structured group training and tailored one-on-one technical walkthroughs for the practice staff.
All training sessions will be delivered by Simple HealthCare Solutions and PenCS team.

There is no patient-level recruitment, no patient-facing intervention, and no direct clinical delivery by the research team; evaluation relies solely on the analysis of aggregated, de-identified practice data. At the practice level, the HMR consultation will be delivered as an individual consultation between the patient and credentialed pharmacist followed by patient-GP interaction and may occur face-to-face or via telehealth, depending on patient preference, clinical appropriateness, and service arrangements.

4. Time duration:
The feasibility intervention timeline is structured as follows:
4.1 Practice Onboarding: A single 30–45 minute virtual onboarding session per practice.
4.2 IT Installation: A single 30–60 minute remote software installation and calibration session per practice.
4.3 Technical Training: A single 120-minute virtual group training session for practice staff, supplemented by remote, ad-hoc technical support throughout the active study period as requested by the sites.
4.4 Data Collection Window: The software tools remain active in the clinics for the duration of the feasibility trial window (June 2026-Dec 2026) to gather automated metrics on system utility and aggregated workflow data.

At the practice level, participants will receive one HMR consultation with the credentialed pharmacist (approximately 45–60 minutes), followed by a GP review appointment (approximately 10-15 minutes) to discuss recommendations and ongoing management. Duration of the broader intervention workflow, including referral and follow-up processes, will align with routine clinical care. Research team will not be involved in this process.

5. Location:
5.1 Technical Training and Support: Conducted virtually/remotely.
5.2 System Deployment: Embedded digitally within the local or cloud-based clinical server environments of the five participating rural general practice clinics
At the practice-pharmacist level, the BRIDGE HMR consultation may be conducted at the general practice clinic, or at a mutually convenient location, or via telehealth, depending on patient preference, accessibility, and local practice arrangements. Research team will not be involved in this process.

6. Compliance and Adherence monitoring:
6.1 Practice-Level Feasibility Monitoring: Technical adherence, system usability, and workflow barriers are documented by the participating practices using a standardized digital implementation log.
6.2 Automated Workflow Triggers: To support the natural integration of the tool without creating administrative burden, the system utilizes pre-existing, automated clinic infrastructure. This includes evaluating the use of targeted SMS notifications sent automatically through the clinic's medical management system to eligible patients who have a pre-existing appointment scheduled at the practice.
6.3 Data collection: The HMR provides automated, backend aggregate level number of HMR referrals generated and completion rates.

Intervention code [1] 334097 0
Early detection / Screening
Intervention code [2] 334098 0
Prevention
Description of the comparator or control
No control group. This is an uncontrolled, single-arm feasibility study evaluating the implementation and acceptability of a technology-enabled process to identify patients who may be eligible for Home Medication Reviews and support referral pathways within rural general practice.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345448 0
The primary aim of this study is to assess the feasibility of implementing and integrating a facilitated pathway combining electronic case-finding, coordinated referral processes, and interprofessional collaboration into routine rural general practice workflows. Accordingly, this study focuses on implementation feasibility and acceptability rather than clinical effectiveness. As this is a feasibility study, feasibility and acceptability will be assessed together as a composite primary outcome.
Timepoint [1] 345448 0
Timepoint: Assessed throughout the implementation period using implementation records and platform data, with qualitative evaluation conducted at 3 months post study commencement and a focus group discussion upon the conclusion of the study.
Secondary outcome [1] 461711 0
Influence of contextual factors (e.g., practice size, workforce structures, relationships with local pharmacists, and previous experience with Home Medicines Reviews (HMR) on the adoption and implementation of BRIDGE across participating rural general practices.
Timepoint [1] 461711 0
Semi-structured interview will be conducted at 3 months post study commencement and focus group discussion upon the conclusion of the study.

Eligibility
Key inclusion criteria
The feasibility study will include five rural and remote general practices. Eligible practices must be located in MMM 3–7 areas of South Australia, have at least one participating GP and a practice nurse, and use either Best Practice or Medical Director clinical management software.

The study is targeting rural and remote practices to assess the feasibility and acceptability of implementing a workflow designed to identify patients who may be at risk of medication-related harm and facilitate appropriate medication review and management.

Patients are not recruited as study participants. Patient-level information is used only within participating practices as part of routine clinical care, and only aggregate, de-identified practice-level data are provided to the research team.

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Practices that do not meet the eligibility criteria (i.e. are not located in MMM 3–7 areas of rural South Australia, do not have at least one participating GP and a practice nurse, or do not use Best Practice or Medical Director clinical management software) will be excluded from participation.

Patients are not recruited as study participants. However, participating practice staff may determine that a patient is not suitable for referral for a Home Medication Review (HMR) if the patient:

1. Does not meet current HMR eligibility or prioritisation requirements under Australian guidelines.
2. Has received an HMR within the previous 12 months, or within the timeframe specified by current HMR guidelines.
3. Is unable to provide informed consent for an HMR referral and no authorised substitute decision-maker is available.
4. Is considered unsuitable for referral based on the treating GP's clinical judgement.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
As this is a feasibility study, analyses will primarily be descriptive in nature. Feasibility and implementation outcomes, including recruitment rates, identification of eligible patients, HMR referral and completion rates, and intervention uptake, will be summarised using descriptive statistics (frequencies, proportions, means, standard deviations, medians, and interquartile ranges, as appropriate). No formal hypothesis testing is planned.
Qualitative feedback and process evaluation data will be analysed using descriptive and thematic approaches, where appropriate.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321838 0
Government body
Name [1] 321838 0
National Health and Medical Research Council (NHMRC)
Country [1] 321838 0
Australia
Primary sponsor type
University
Name
Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 324691 0
None
Name [1] 324691 0
Address [1] 324691 0
Country [1] 324691 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320380 0
Royal Australian College of General Practitioners National Research and Evaluation Ethics Committee
Ethics committee address [1] 320380 0
Ethics committee country [1] 320380 0
Australia
Date submitted for ethics approval [1] 320380 0
30/03/2026
Approval date [1] 320380 0
22/06/2026
Ethics approval number [1] 320380 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150290 0
A/Prof David Gonzalez
Address 150290 0
Adelaide University, 115 Grenfell Street, Level 8, Room 8.11c, Adelaide, 5000, SA, Australia
Country 150290 0
Australia
Phone 150290 0
+61 8 83131631
Fax 150290 0
Email 150290 0
Contact person for public queries
Name 150291 0
Dr Deepti Sharma
Address 150291 0
Adelaide University, 115 Grenfell Street, Level 8, Room 8.14, Adelaide, 5000, SA, Australia
Country 150291 0
Australia
Phone 150291 0
+61 8 83135861
Fax 150291 0
Email 150291 0
Contact person for scientific queries
Name 150292 0
Deepti Sharma
Address 150292 0
Adelaide University, 115 Grenfell Street, Level 8, Room 8.14, Adelaide, 5000, SA, Australia
Country 150292 0
Australia
Phone 150292 0
+61 8 83135861
Fax 150292 0
Email 150292 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: This is a feasibility study, and no identifiable individual patient-level data will be collected. Analyses will be based on aggregated practice-level and implementation data only. Therefore, individual participant data sharing is not applicable.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.